...
NRIXSMALL

Nurix Therapeutics, Inc.

HealthcareBiotechnology
$15.97
$0.00(-0.87%)
52W$8.18
$22.50
FinancialsValuationvs REGN
Updated Mar 2, 12:00 AM
RSI45
RS Rating76/99
Beta1.19
Volatility68%
F-Score4/9
Mkt Cap$1.6B
EMERGING TREND

Price Action

5Y Daily
50 DMA150 DMA200 DMA

Technical Summary

EMERGING TREND

Nurix Therapeutics, Inc. shows underlying uptrend characteristics but has temporarily lost support at the 50-day moving average. Relative strength is moderate (RS Rating: 76), indicating performance broadly in line with the market. Earnings contraction of 9% provides fundamental context to the price action. Investors should exercise caution due to high volatility (68% annualized), which requires wider risk management.

Relative Strength
76
out of 99
Average
Trend Score
3/4
Minervini Criteria
EMERGING TREND
Risk (Beta)
1.19
vs S&P 500
ABOVE MKT
52W Position
54%
from 52W low
Mid Range
Trend & Momentum Analysis

Trend Template (Minervini)

EMERGING TREND3/4 Criteria Met
CriterionValueStatus
Price > 50 SMA$17.66
50 SMA > 100 SMA$15.76
100 SMA > 150 SMA$13.74
150 SMA > 200 SMA$13.19

Price vs Moving Averages

PeriodValueSpreadSignal
20 SMA$16.12-0.96%BELOW
50 SMA$17.66-9.58%BELOW
100 SMA$15.76+1.34%ABOVE
150 SMA$13.74+16.24%ABOVE
200 SMA$13.19+21.10%ABOVE

Price Performance

1D-0.9%
1W+3.8%
1M-10.6%
3M-9.7%
6M+69.7%
YTD-11.6%
1Y+3.4%
3Y+19.2%
52-Week Trading Range54% from low
$15.97
52W Low$8.18
52W High$22.50

Technical Indicators

RSI (14)NEUTRAL
45.3
305070
VCP ScoreCOOL
5/10
Base depth: 46.6%

Risk Profile

Beta
1.19
52W Vol
68%
ATR
$0.72
Max DD (1Y)
-47%

Volume Analysis

Today
15
50D Avg
945.6K
Vol Ratio
0.00x
Liquidity
MODERATE

Earnings Momentum

Q1'25+12%
$-0.67
Q2'25+27%
$-0.52
Q3'25-54%
$-1.03
Q4'25-9%
$-0.82
Fundamentals & Growth

Growth Trends

Compounded Sales Growth

10 Years:—
5 Years:+36.35%
3 Years:+29.55%
TTM:+53.95%

Compounded Profit Growth

10 Years:—
5 Years:—
3 Years:—
TTM:-5.19%

Stock Price CAGR

10 Years:-1.73%
5 Years:-15.12%
3 Years:+19.20%
1 Year:+3.37%

Return on Equity

10Y Avg:-48.3%
5Y Avg:-50.6%
3Y Avg:-53.3%
Last Year:-49.1%

Key Metrics

Market Cap$1.6B
Gross Margin77.5%
Net Margin-3.1%
Piotroski F-Score4/9

More NRIX Analysis

Full Financial AnalysisDCF & Intrinsic ValueTotal Return Calculator

Compare With

NRIX vs REGNREGNCNTAIMNMCLDX

Data Dictionary

RS Rating (Relative Strength)

Measures 12-month price performance vs all stocks. Rating of 76 meansNRIX outperformed 76% of all stocks. Scores >80 indicate market leaders.

Beta

Measures volatility vs S&P 500. Beta of 1.19 means 19% more volatile than market.

Piotroski F-Score

9-point financial strength score based on profitability, leverage, and efficiency. Score of 4/9. Scores 7-9 = strong, 4-6 average, 0-3 = weak.

VCP (Volatility Contraction Pattern)

Measures base formation quality. Higher scores indicate tighter consolidation near pivot points. Score of 5/10 with COOL status.

Frequently Asked Questions

Is NRIX in an uptrend right now?

NRIX has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.

Is NRIX overbought or oversold?

NRIX's RSI (14) is 45. The stock is in neutral territory, neither overbought nor oversold.

Is NRIX outperforming the market?

NRIX has a Relative Strength (RS) Rating of 76 out of 99. NRIX is performing about average compared to the market.

Where is NRIX in its 52-week range?

NRIX is trading at $15.97, which is 71% of its 52-week high ($22.50) and 54% above its 52-week low ($8.18).

How volatile is NRIX?

NRIX has a Beta of 1.19 and 52-week volatility of 68%. It's more volatile than the S&P 500 - expect bigger swings.